Pharmaceutics (Jan 2022)

EGFR-Targeted Photodynamic Therapy

  • Luca Ulfo,
  • Paolo Emidio Costantini,
  • Matteo Di Giosia,
  • Alberto Danielli,
  • Matteo Calvaresi

DOI
https://doi.org/10.3390/pharmaceutics14020241
Journal volume & issue
Vol. 14, no. 2
p. 241

Abstract

Read online

The epidermal growth factor receptor (EGFR) plays a pivotal role in the proliferation and metastatization of cancer cells. Aberrancies in the expression and activation of EGFR are hallmarks of many human malignancies. As such, EGFR-targeted therapies hold significant potential for the cure of cancers. In recent years, photodynamic therapy (PDT) has gained increased interest as a non-invasive cancer treatment. In PDT, a photosensitizer is excited by light to produce reactive oxygen species, resulting in local cytotoxicity. One of the critical aspects of PDT is to selectively transport enough photosensitizers to the tumors environment. Accordingly, an increasing number of strategies have been devised to foster EGFR-targeted PDT. Herein, we review the recent nanobiotechnological advancements that combine the promise of PDT with EGFR-targeted molecular cancer therapy. We recapitulate the chemistry of the sensitizers and their modes of action in PDT, and summarize the advantages and pitfalls of different targeting moieties, highlighting future perspectives for EGFR-targeted photodynamic treatment of cancer.

Keywords